| CpG DNA induces stronger immune responses with less toxicity than other adjuvants RD Weeratna, MJ McCluskie, Y Xu, HL Davis Vaccine 18 (17), 1755-1762, 2000 | 393 | 2000 |
| Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice MJ McCluskie, HL Davis The Journal of Immunology 161 (9), 4463-4466, 1998 | 386 | 1998 |
| DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. HL Davis, MJ McCluskie, JL Gerin, RH Purcell Proceedings of the National Academy of Sciences 93 (14), 7213-7218, 1996 | 322 | 1996 |
| Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract WS Gallichan, RN Woolstencroft, T Guarasci, MJ McCluskie, HL Davis, ... The Journal of Immunology 166 (5), 3451-3457, 2001 | 294 | 2001 |
| Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates MJ McCluskie, CLB Millan, RA Gramzinski, HL Robinson, JC Santoro, ... Molecular Medicine 5, 287-300, 1999 | 280 | 1999 |
| TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848) RD Weeratna, SR Makinen, MJ McCluskie, HL Davis Vaccine 23 (45), 5263-5270, 2005 | 204 | 2005 |
| Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation J Vollmer, RD Weeratna, M Jurk, U Samulowitz, MJ Mccluskie, P Payette, ... Immunology 113 (2), 212-223, 2004 | 200 | 2004 |
| Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants MJ McCluskie, HL Davis Vaccine 19 (4-5), 413-422, 2000 | 199 | 2000 |
| CpG DNA is an effective oral adjuvant to protein antigens in mice MJ McCluskie, RD Weeratna, AM Krieg, HL Davis Vaccine 19 (7-8), 950-957, 2000 | 169 | 2000 |
| DNA vaccines for viral diseases HL Davis, MJ McCluskie Microbes and Infection 1 (1), 7-21, 1999 | 138 | 1999 |
| Methods and compositions for inducing innate immune responses HL Davis, MJ Mccluskie, DP Drane | 136 | 2006 |
| CpG DNA as mucosal adjuvant MJ McCluskie, HL Davis Vaccine 18 (3-4), 231-237, 1999 | 136 | 1999 |
| CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice RD Weeratna, CL Brazolot Millan, MJ McCluskie, HL Davis FEMS Immunology & Medical Microbiology 32 (1), 65-71, 2001 | 135 | 2001 |
| DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice HL Davis, CLB Millan, M Mancini, MJ McCluskie, M Hadchouel, ... Vaccine 15 (8), 849-852, 1997 | 122 | 1997 |
| Immunostimulatory nucleic acids for inducing a Th2 immune response M McCluskie, H Davis US Patent App. 09/768,012, 2001 | 121 | 2001 |
| Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA MJ McCluskie, AM Krieg From innate immunity to immunological memory, 155-178, 2006 | 114 | 2006 |
| Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs Y Chen, P Lenert, R Weeratna, M McCluskie, T Wu, HL Davis, AM Krieg Gene therapy 8 (13), 1024-1032, 2001 | 98 | 2001 |
| Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA MJ McCluskie, RD Weeratna, PJ Payette, HL Davis FEMS Immunology & Medical Microbiology 32 (3), 179-185, 2002 | 96 | 2002 |
| Novel adjuvant systems MJ McCluskie, RD Weeratna Current Drug Targets-Infectious Disorders 1 (3), 263-271, 2001 | 96 | 2001 |
| Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution MJ McCluskie, RD Weeratna, HL Davis Molecular medicine 6, 867-877, 2000 | 94 | 2000 |
Lakshmi KrishnanNational Research CouncilVerified email at nrc-cnrc.gc.ca
